Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Depo-estradiol
2. Estradiol 17 Beta-cyclopentanepropionate
3. Estradiol 17 Beta-cyclopentylpropionate
4. Estradiol 17 Beta-cypionate
1. 313-06-4
2. Depofemin
3. Depoestradiol
4. Depo-estradiol
5. Depoestra
6. Estradep
7. Estrapo
8. Estro-depo
9. Dep-estro
10. Femogen Cyp
11. Depgynogen
12. Depoestradiol Cypionate
13. Beta-estradiol 17-cypionate
14. Estradiol 17-cypionate
15. Estradiol Cyclopentylpropionate
16. Estradiol (cypionate)
17. E. Ionate P.a.
18. Estradiol 17-cyclopentylpropionate
19. Depo-estradiol Cyclopentylpropionate
20. Nsc 3354
21. Estradiol Cipionate
22. Estradiol, 17-cyclopentanepropionate
23. Cyclopentanepropionic Acid, 17-ester With Estradiol
24. Nsc-3354
25. Estradiol Cypionate [usp]
26. 17.beta.-estradiol Cypionate
27. Estradiol 17.beta.-cypionate
28. 7e1dv054lo
29. Chebi:34745
30. Nsc3354
31. Estra-1,3,5(10)-triene-3,17-diol(17b)-, 17-cyclopentanepropanoate
32. Estradiol 17beta-cyclopentylpropionate
33. 17.beta.-estradiol Cyclopentylpropionate
34. Estradiol 17.beta.-cyclopentylpropionate
35. 17.beta.-estradiol Cyclopentanepropionate
36. Estradiol 17.beta.-cyclopentanepropanoate
37. Estradiol 17.beta.-cyclopentanepropionate
38. Pertradiol
39. 17.beta.-estradiol 17-cyclopentylpropionate
40. Dsstox_cid_2999
41. Estradiol Cypionate (usp)
42. Neoginon Depositum
43. Dsstox_rid_76824
44. Dsstox_gsid_22999
45. Ecp (van)
46. Estradiol 17beta-cypionate
47. [(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
48. Cas-313-06-4
49. Smr000058700
50. Estradiol 17-cyclopentanepropionate
51. Einecs 206-237-8
52. Estradiol 17beta-cylopentylpropionate
53. Estradiol 17beta-cyclopentanepropionate
54. Brn 3171075
55. Unii-7e1dv054lo
56. Depestro
57. 17beta-estradiol 17-cyclopentylpropionate
58. Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 17-cyclopentanepropanoate
59. Estradiol-cypionate
60. Ncgc00166134-01
61. Mfcd00056558
62. Depo-estradiol (tn)
63. Estradiol Cypionate Salt
64. Schembl41551
65. 4-09-00-00047 (beilstein Handbook Reference)
66. Mls000069763
67. Mls001074891
68. 17beta-estradiol 17-cypionate
69. Chembl1200973
70. Dtxsid4022999
71. Hms2234k11
72. Estradiol Cypionate [vandf]
73. (8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthren-17-yl 3-cyclopentylpropanoate
74. Bcp11930
75. Estradiol Cipionate [mart.]
76. Hy-b1100
77. Zinc3876078
78. Tox21_110003
79. Tox21_112331
80. Tox21_301818
81. Estra-1,3,5(10)-triene-3,17beta-diol 17-(cyclopentanepropionate)
82. Estradiol Cipionate [who-dd]
83. Estradiol Cypionate [usp-rs]
84. Estradioli Cypionas [who-ip]
85. S4046
86. (17beta)-3-hydroxyestra-1(10),2,4-trien-17-yl 3-cyclopentylpropanoate
87. Akos015895730
88. Cyclopentanepropionic Acid, 3-hydroxyestra-1,3,5(10)-trien-17beta-yl Ester
89. Estra-1,3,5(10)-triene-3,17-diol (17beta)-, 17-cyclopentanepropanoate
90. Estra-1,3,5(10)-triene-3,17-diol, (17beta)-, 17-cyclopentanepropanoate
91. Tox21_112331_1
92. .beta.-estradiol 17-cypionate
93. Beta-estradiol 17-cyclopentylpropionate
94. Ccg-268613
95. Cs-4691
96. Db13954
97. Ks-5296
98. Estradiol 17.beta.-cylopentylpropionate
99. Estradiol Cypionate [orange Book]
100. Ncgc00013034-01
101. Ncgc00166134-02
102. Ncgc00166134-03
103. Ncgc00255333-01
104. (1s,11s,14s,15s,10r)-5-hydroxy-15-methyltetracyclo[8.7.0.0<2,7>.0<11,15>]hepta Deca-2,4,6-trien-14-yl 3-cyclopentylpropanoate
105. Nci60_002938
106. Estradiol Cypionate [usp Monograph]
107. Estradiol-17-cyclopentanepropionate
108. Lunelle Component Estradiol Cypionate
109. E0875
110. D04063
111. Estradiol Cypionate Component Of Lunelle
112. 313d064
113. Depo-testadiol Component Estradiol Cypionate
114. Q5401760
115. W-106910
116. Estradiol 17.beta.-cyclopentanepropanoate [mi]
117. Estradiol Cypionate Component Of Depo-testadiol
118. (17?)-3-hydroxyestra-1,3,5(10)-trien-17-yl 3-cyclopentylpropanoate
119. 17.beta.-[(3-cyclopentylpropanoyl)oxy]estra-1,3,5(10)-trien-3-ol
120. Estra-1,5(10)-triene-3,17-diol (17.beta.)-, 17-cyclopentanepropanoate
121. Estra-1,5(10)-triene-3,17-diol, (17.beta.)-, 17-cyclopentanepropanoate
122. Estradiol Cypionate, United States Pharmacopeia (usp) Reference Standard
123. (17.beta.)-estra-1,3,5(10)-triene-3,17-diol 17.beta.-cyclopentanepropanoate
124. Cyclopentanepropionic Acid, 3-hydroxyestra-1,3,5(10)-trien-17.beta.-yl Ester
125. Estra-1,3,5(10)-triene-3,17-diol, (17.beta.)-, 17-cyclopentanepropanoate
| Molecular Weight | 396.6 g/mol |
|---|---|
| Molecular Formula | C26H36O3 |
| XLogP3 | 7.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Exact Mass | 396.26644501 g/mol |
| Monoisotopic Mass | 396.26644501 g/mol |
| Topological Polar Surface Area | 46.5 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 597 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Depo-Estradiol intramuscular depot injection is indicated for the treatment of moderate to severe vasomotor symptoms and hypoestrogenism due to hypogonadism.
FDA Label
Estrogen mediates its effects across the body through potent agonism of the Estrogen Receptor (ER), which is located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain. Estradiol binds to both subtypes of the Estrogen Receptor: Estrogen Receptor Alpha (ER) and Estrogen Receptor Beta (ER). Estradiol also acts as a potent agonist of G Protein-coupled Estrogen Receptor (GPER), which has recently been recognized as a major mediator of estradiol's rapid cellular effects.
Contraceptive Agents, Hormonal
Contraceptive agents that act on the ENDOCRINE SYSTEM. (See all compounds classified as Contraceptive Agents, Hormonal.)
Contraceptive Agents, Female
Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading. (See all compounds classified as Contraceptive Agents, Female.)
Absorption
When conjugated with aryl and alkyl groups for parenteral administration, the rate of absorption of oily preparations is slowed with a prolonged duration of action, such that a single intramuscular injection of estradiol valerate or estradiol cypionate is absorbed over several weeks.
Route of Elimination
Estradiol, estrone and estriol are excreted in the urine along with glucuronide and sulfate conjugates.
Volume of Distribution
The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs.
Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.
Estradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. Increases in the down-stream effects of ER binding reverses some of the symptoms of menopause and of hypoestrogenism, which are primarily caused by a loss of estrogenic activity.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
